IRLAB Therapeutics - All steady as key catalyst approaches
The Phase IIb trial of mesdopetam (partnered with Ipsen) in levodopa-induced dyskinesias in Parkinson’s disease (PD-LIDs) remains a key value driver for IRLAB and top-line data is on track to be reported around the year end 2022. Following the Ipsen deal in 2021, the company has, in our view, further demonstrated the utility of its Integrative Screening Process, progressing pirepemat into Phase IIb trials in PD-related falls and selecting two new preclinical candidates (IRL942 and IRL757). The company recorded SEK32.5m in revenue in H122, primarily relating to the Ipsen licensing agreement and services provided. R&D expenses over the period rose to SEK75.7m (85% of total operating costs) from SEK38.5m in H121, as pirepemat Phase IIb clinical trials commenced and preparations for Phase I trials with preclinical assets began. At end-H122, IRLAB had net cash of SEK322.6m which, at the current burn rate (H122: SEK77.8m) we anticipate will fund the company into FY24. We value IRLAB at SEK6.40bn or SEK123.7per share (previously SEK6.13bn or SEK118.5/share).IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson's disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson's Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.